Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Ponatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), was devel···【more】
Release date：2026-01-20Recommended：112
On March 19, Takeda announced that the U.S. Food and Drug Administration (FDA) h···【more】
Release date：2026-01-20Recommended：141
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the Phase···【more】
Release date：2026-01-20Recommended：152
During treatment with pralsetinib, it is imperative that you inform your healthc···【more】
Release date：2026-01-16Recommended：98
While certain medications should not be used together at all, in other cases, tw···【more】
Release date：2026-01-16Recommended：118
Please keep all scheduled appointments with your doctor and the laboratory on ti···【more】
Release date：2026-01-16Recommended：103
Pralsetinib may interfere with the efficacy of hormonal contraceptives (includin···【more】
Release date：2026-01-16Recommended：127
Although severe adverse reactions to Pralsetinib (brand name: Gavreto) are relat···【more】
Release date：2026-01-16Recommended：108
Pralsetinib is indicated for the treatment of adult patients with specific types···【more】
Release date：2026-01-16Recommended：122
The efficacy of Pralsetinib was investigated in a multicenter, open-label, multi···【more】
Release date：2026-01-16Recommended：76
Pralsetinib is the sixth drug under Genentech that has obtained FDA approval for···【more】
Release date：2026-01-16Recommended：110
Please take pralsetinib strictly in accordance with the instructions of medical ···【more】
Release date：2026-01-16Recommended：107
